MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-31-2023
Ayala Pharmaceuticals Revenue 2011-2026 | AYLA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 692 K | 3.51 M | 3.71 M | 2.33 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.71 M | 692 K | 2.56 M |
Quarterly Revenue Ayala Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 91 K | 38 K | 458 K | - | 625 K | 761 K | 974 K | - | 658 K | 1.04 M | 1 M | - | 845 K | 852 K | 265 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.04 M | 38 K | 634 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
18.7 M | $ 3.01 | 3.79 % | $ 233 M |  USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.08 | 0.65 % | $ 7.41 B |  Australia |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.99 | 1.02 % | $ 508 M |  Britain |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
364 M | $ 213.24 | 1.87 % | $ 5 B |  Danmark |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M |  Canada |
 |
Bellicum Pharmaceuticals
BLCM
|
1.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
60.3 M | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
29.5 M | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
482 M | $ 95.2 | -0.08 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 0.2 | 8.46 % | $ 435 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 26.78 | -0.81 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
3.81 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
167 M | $ 9.61 | 0.63 % | $ 141 M | USA |
 |
Catalyst Biosciences
CBIO
|
113 M | $ 11.86 | 2.24 % | $ 781 M | USA |
 |
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | USA |
 |
Certara
CERT
|
385 M | $ 8.81 | -0.56 % | $ 1.41 B | USA |
 |
Celldex Therapeutics
CLDX
|
7.02 M | $ 27.16 | 2.76 % | $ 1.75 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
54 K | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Cellectis S.A.
CLLS
|
41.5 M | $ 4.84 | 1.26 % | $ 116 M |  France |
 |
Axon Enterprise
AXON
|
2.08 B | $ 567.93 | -0.73 % | $ 43 B | USA |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.6 | 1.96 % | $ 16.3 M | USA |
 |
AstraZeneca PLC
AZN
|
54.1 B | $ 91.93 | -0.63 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
8.01 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
330 M | $ 8.92 | -1.0 % | $ 1.46 B | Britain |
 |
ChromaDex Corporation
CDXC
|
99.6 M | - | -0.88 % | $ 598 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
463 M | $ 11.29 | -3.01 % | $ 730 M | USA |